Introduction: Posterior urethral valve (PUV) is a major cause of congenital bladder dysfunction, often persisting despite treatment. Emerging therapies, including anticholinergics and α-1 blockers, offer potential but lack clear guidelines. This study evaluates their effectiveness in improving bladder function after valve fulguration. Methods: Twenty PUV patients, aged ≥3 years, were randomized into anticholinergic (group A, n = 11) and α-1 adrenergic blocker (group B, n = 9) groups post-fulguration. Follow-up included clinical, radiological, and urodynamic assessments 6 months posttreatment initiation. Results: In group A, the mean maximum detrusor pressure (Pdet) decreased from 30.17 to 23.45 cm H2O (p = 0.033). Two patients normalized from high detrusor pressure (>40 cm H2O). In group B, 1 patient retained high detrusor pressure posttreatment. Group B improved in average urinary flow (Q avg) and maximum flow rate (Q max), with all patients having initially low Q avg (<10 mL/s). Two group B patients showed improved average flow rates posttreatment (p = 0.016); three in group A showed improvement but were not statistically significant (p = 0.197). Q max/flow time ratio was abnormal in all group B patients pretreatment. Two of the nine improved posttreatment, while only one in group A did. Conclusions: Anticholinergic medications positively impact cystometric parameters and are effective for detrusor instability and low compliance bladder. α-Adrenergic blockers influence uroflow parameters and can help treat bladder outflow obstruction. Consideration for a larger study with extended follow-up is warranted.

1.
Peters
CA
,
Vasavada
S
,
Dator
D
,
Carr
M
,
Shapiro
E
,
Lepor
H
, et al
.
The effect of obstruction on the developing bladder
.
J Urol
.
1992
;
148
(
2 Pt 2
):
491
6
.
2.
Lopez Pereira
P
,
Espinosa
L
,
Martinez Urrutina
MJ
,
Lobato
R
,
Navarro
M
,
Jaureguizar
E
.
Posterior urethral valves: prognostic factors
.
BJU Int
.
2003
;
91
(
7
):
687
90
.
3.
Casey
JT
,
Hagerty
JA
,
Maizels
M
,
Chaviano
AH
,
Yerkes
E
,
Lindgren
BW
, et al
.
Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves
.
J Urol
.
2012
;
188
(
4 Suppl
):
1516
20
.
4.
Wani
SA
,
Babu
N
,
Faheem
M
,
Jadhav
V
,
Ramesh
S
,
Deepak
J
.
Early use of bladder relaxant (oxybutynin) in posterior urethral valve patients. Is it justified
.
Med Sur Urol
.
2019
;
8
:
222
.
5.
Abraham
MK
,
Nasir
ARA
,
Sudarsanan
B
,
Puzhankara
R
,
Kedari
PM
,
Unnithan
GR
, et al
.
Role of alpha-adrenergic blocker in the management of posterior urethral valves
.
Pediatr Surg Int
.
2009
;
25
(
12
):
1113
5
.
6.
Drzewiecki
BA
,
Bauer
SB
.
Urodynamic testing in children: indications, technique, interpretation and significance
.
J Urol
.
2011
;
186
(
4
):
1190
7
.
7.
Yeung
CK
,
Sihoe
JDY
,
Bauer
SB
.
Voiding dysfunction in children: non-neurogenic and neurogenic
. In:
Wein
AJ
,
Kavoussi
LR
,
Novick
AC
, et al
, editors.
Campbell-walsh urology
. 9th ed.
Philadelphia
:
Saunders Elsevier
;
2007
. p.
3604
55
.
8.
Houle
AM
,
Gilmour
RF
,
Churchill
BM
,
Gaumond
M
,
Bissonnette
B
.
What volume can a child normally store in the bladder at a safe pressure
.
J Urol
.
1993
;
149
(
3
):
561
4
.
9.
Neveus
T
,
Von Gontard
A
,
Hoebeke
P
,
Hjalmas
K
,
Bauer
S
,
Bower
W
, et al
.
The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society
.
J Urol
.
2006
;
176
(
1
):
314
24
.
10.
Nijman
RJM
,
Bower
W
,
Butler
V
, et al
.
Diagnosis and management of urinary incontinence and encopresis in childhood
. In:
Abrams
P
,
Cordozo
L
,
Khoury
S
, et al
, editors.
3rd International consultation on incontinence
.
Paris
:
Health Publications Ltd
;
2005
. p.
967
1057
.
11.
Chertin
B
,
Cozzi
D
,
Puri
P
.
Long-term results of primary avulsion of posterior urethral valves using a Fogarty balloon catheter
.
J Urol
.
2002
;
168
(
4 Pt 2
):
1841
3
.
12.
Lopez Pereira
P
,
Martinez Urrutia
MJ
,
Espinosa
L
,
Lobato
R
,
Navarro
M
,
Jaureguizar
E
.
Bladder dysfunction as a prognostic factor in patients with posterior urethral valves
.
BJU Int
.
2002
;
90
(
3
):
308
11
.
13.
Glassberg
KI
,
Weinstein
RB
,
Combs
AJ
, et al
.
When can persistent upper tract dilation be accepted as residual dilatation in posterior urethral valve patients?
In:
Presented at annual meeting of society for pediatric urology, Atlanta, Georgia
;
2000
.
14.
Horowitz
M
,
Misseri
R
.
Diurnal and nocturnal enuresis
. In:
Docimo
S
,
Canning
D
,
Khoury
A
,
Salle
JLP
, editors.
The kelalis-king-belman textbook of clinical pediatric urology
.
Boca Raton
:
CRC Press
;
2006
. p.
819
40
.
15.
Norris
J
,
Raj
J
,
Thomas
T
,
Maleperambil
T
,
Shubha
A
.
Effects of oxybutynin in children with posterior urethral valves post fulguration: report in a select cohort of children
.
J Fam Med Prim Care
.
2021
;
10
:
3706
11
.
16.
Misseri
R
,
Combs
AJ
,
Horowitz
M
,
Donohoe
JM
,
Glassberg
KI
.
Myogenic failure in posterior urethral valve disease: real or imagined
.
J Urol
.
2002
;
168
(
4 Pt 2
):
1844
8
.
17.
Donohoe
JM
,
Combs
AJ
,
Glassberg
KI
.
Primary bladder neck dysfunction in children and adolescents II: results of treatment with α-adrenergic antagonists
.
J Urol
.
2005
;
173
(
1
):
212
6
.
18.
Singh
SK
,
Sharma
V
,
Singh
A
,
Shrivastava
A
.
Role of alpha adrenergic blocker on bladder emptying in children with posterior urethral valve after valve ablation
.
Sch Acad J Biosci
.
2017
;
5
:
759
61
.
You do not currently have access to this content.